

Resource Summary Report

Generated by PRECISE-TBI on Aug 27, 2026

Blueprint Neurotherapeutics Network

RRID:SCR_008829

Type: Tool

Proper Citation

Blueprint Neurotherapeutics Network (RRID:SCR_008829)

Resource Information

URL: <http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm>

Proper Citation: Blueprint Neurotherapeutics Network (RRID:SCR_008829)

Description: A network that provides support and NIH funding for neuroscience research and drug development through access to contract research organizations for outsourcing and research consultation. Successful applicants will receive funding to conduct biological testing, access to a full range of industry-style drug development services and expertise, and control of the intellectual property for drug candidates. Funded projects include treatments for age-related macular degeneration, ALS, Alzheimer's disease, depression, hearing loss, optic neuropathy and stroke.

Abbreviations: BPN

Synonyms: NIH Blueprint Neurotherapeutics Network

Resource Type: funding resource

Keywords: drug, drug development, age-related macular degeneration, amyotrophic lateral sclerosis, alzheimer's disease, depressive disorder, hearing loss, optic neuropathy, stroke, drug discovery, neurological disorder, funding resource

Funding: NIH Blueprint for Neuroscience Research

Resource Name: Blueprint Neurotherapeutics Network

Resource ID: SCR_008829

Alternate IDs: nlx_144566

Record Creation Time: 20220129T080249+0000

Record Last Update: 20260815T182344+0000

Ratings and Alerts

No rating or validation information has been found for Blueprint Neurotherapeutics Network.

No alerts have been found for Blueprint Neurotherapeutics Network.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Zheng M, et al. (2015) The role of Abcb5 alleles in susceptibility to haloperidol-induced toxicity in mice and humans. PLoS medicine, 12(2), e1001782.